secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001193125-25-314994
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant prices $550M stock offering; updates IMVT-1402 and batoclimab timelines
--------------------------------------------------------------------------------

- Underwritten common stock offering of ~$550M gross proceeds; Roivant Sciences to purchase shares; expected close Dec 12, 2025.
- Potentially registrational D2T RA trial of IMVT-1402: top-line results now expected in 2026 (previously initial open-label only in 2026).
- Batoclimab Phase 3 TED studies: top-line results delayed to H1 2026 (previously by end of 2025); results shared concurrently.
- Discussions commenced with HanAll to potentially return batoclimab rights; may result in dispute or arbitration.
- Existing cash plus offering proceeds expected to fund operations through potential commercial launch of IMVT-1402 in Graves' Disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000119312525314994/0001193125-25-314994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000119312525314994/d760155d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-314994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer